BioCentury
ARTICLE | Company News

EC approves Chiesi's stem cells for the eye

February 21, 2015 1:42 AM UTC

The European Commission granted conditional marketing authorization for Holoclar from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat adults with moderate to severe limbal stem cell deficiency (LSCD) due to physical or chemical burns to the eyes.

Holoclar is the first advanced therapy medicinal product (ATMP) containing stem cells approved in Europe and had Orphan Drug designation in the EU for LSCD. ...